Santen gains rights to TRACON's entoglin antibodies for eye uses
This article was originally published in Scrip
Executive Summary
Santen Pharmaceutical has acquired exclusive global rights to TRACON Pharmaceuticals' portfolio of anti-endoglin antibodies for use in ophthalmology indications, gaining access to a potential new therapy for wet age-related macular degeneration (AMD).